{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:01:15Z","timestamp":1780434075456,"version":"3.54.1"},"reference-count":21,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>The current landscape and treatment patterns of disease-modifying therapy (DMT) use in pediatric patients with multiple sclerosis (MS) are not yet well understood. This study examined DMT utilization and treatment patterns in pediatric patients newly diagnosed as having MS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Pediatric patients (&amp;lt;18 years old) with two MS diagnosis claims from January 1, 2010, to December 31, 2016, were identified from the MarketScan Commercial Database. The index date was defined as the date of first MS diagnosis, and patients were followed up for 1 year post-index date. Outcomes evaluated included percentage of patients who initiated treatment after MS diagnosis, different DMTs initiated, treatment discontinuation, and switching treatment during follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Of 182,057 patients newly diagnosed as having MS, 288 pediatric patients (mean age, 14 years; 61% female) were identified. Within the first year of diagnosis, 188 patients (65.3%) did not receive any DMT. The most common first-initiated treatments were interferons and glatiramer acetate (83%), but 28% of patients switched or discontinued from first-initiated treatment within 6 months of treatment initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>This study suggests that a considerable proportion of pediatric patients with MS remain untreated within 1 year of diagnosis. Patients most commonly initiated injectables as their first DMT. Overall, therapy failed early in approximately one in three patients. Thus, the study warrants urgency in treating these patients with currently approved treatment options.<\/jats:p>\n               <\/jats:sec>","DOI":"10.7224\/1537-2073.2019-095","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T15:17:12Z","timestamp":1591111032000},"page":"101-105","source":"Crossref","is-referenced-by-count":10,"title":["Utilization and Treatment Patterns of Disease-Modifying Therapy in Pediatric Patients with Multiple Sclerosis in the United States"],"prefix":"10.7224","volume":"23","author":[{"given":"Benjamin","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kolodny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmay","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"2021062118210887400_i1537-2073-23-3-101-b1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1474-4422(14)70093-6","article-title":"Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research","volume":"13","author":"Waldman","year":"2014","journal-title":"Lancet Neurol."},{"key":"2021062118210887400_i1537-2073-23-3-101-b2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","article-title":"Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years","volume":"3","author":"Benson","year":"2014","journal-title":"Mult Scler Relat Disord."},{"key":"2021062118210887400_i1537-2073-23-3-101-b3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archneurol.2008.505","article-title":"Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch Neurol."},{"key":"2021062118210887400_i1537-2073-23-3-101-b4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ejpn.2010.02.003","article-title":"School performance in a cohort of children with CNS inflammatory demyelination","volume":"14","author":"Mikaeloff","year":"2010","journal-title":"Eur J Paediatr Neurol."},{"key":"2021062118210887400_i1537-2073-23-3-101-b5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458511430704","article-title":"Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis","volume":"18","author":"Chitnis","year":"2012","journal-title":"Mult Scler."},{"key":"2021062118210887400_i1537-2073-23-3-101-b6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1352458510375568","article-title":"The management of multiple sclerosis in children: a European view","volume":"16","author":"Ghezzi","year":"2010","journal-title":"Mult Scler."},{"key":"2021062118210887400_i1537-2073-23-3-101-b7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N Engl J Med."},{"key":"2021062118210887400_i1537-2073-23-3-101-b8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1177\/1352458516675039","article-title":"Importance of early treatment initiation in the clinical course of multiple sclerosis","volume":"23","author":"Kavaliunas","year":"2017","journal-title":"Mult Scler."},{"key":"2021062118210887400_i1537-2073-23-3-101-b9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11940-016-0420-7","article-title":"Use of disease-modifying therapies in pediatric MS","volume":"18","author":"Simone","year":"2016","journal-title":"Curr Treat Options Neurol."},{"key":"2021062118210887400_i1537-2073-23-3-101-b10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"key":"2021062118210887400_i1537-2073-23-3-101-b11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.msard.2018.10.014","article-title":"Puberty onset and pediatric multiple sclerosis activity in boys","volume":"27","author":"Young","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"2021062118210887400_i1537-2073-23-3-101-b12","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/0883073816638754","article-title":"Clinical characteristics of pediatric-onset and adult-onset multiple sclerosis in Hispanic Americans","volume":"31","author":"Langille","year":"2016","journal-title":"J Child Neurol."},{"key":"2021062118210887400_i1537-2073-23-3-101-b13","doi-asserted-by":"crossref","first-page":"e1778","DOI":"10.1212\/WNL.0000000000006471","article-title":"Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US","volume":"91","author":"Krysko","year":"2018","journal-title":"Neurology."},{"key":"2021062118210887400_i1537-2073-23-3-101-b14","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/1352458509345902","article-title":"Fatigue and quality of life in pediatric multiple sclerosis","volume":"15","author":"MacAllister","year":"2009","journal-title":"Mult Scler."},{"key":"2021062118210887400_i1537-2073-23-3-101-b15","first-page":"83","article-title":"Comorbid conditions and medication utilization among pediatric-onset multiple sclerosis patients in the United States","volume":"23","author":"Wenten","year":"2015","journal-title":"Mult Scler."},{"key":"2021062118210887400_i1537-2073-23-3-101-b16","doi-asserted-by":"crossref","first-page":"A105","DOI":"10.1016\/j.jval.2013.03.499","article-title":"Perceptions of multiple sclerosis and disease modifying therapies among currently untreated MS patients","volume":"16","author":"Suh","year":"2013","journal-title":"Value Health."},{"key":"2021062118210887400_i1537-2073-23-3-101-b17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN\u03b2-1b trial","volume":"78","author":"Goodin","year":"2012","journal-title":"Neurology."},{"key":"2021062118210887400_i1537-2073-23-3-101-b18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archneurol.2010.325","article-title":"Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis","volume":"68","author":"Yeh","year":"2011","journal-title":"Arch Neurol."},{"key":"2021062118210887400_i1537-2073-23-3-101-b19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-014-0336-z","article-title":"Treatment of pediatric multiple sclerosis","volume":"17","author":"Narula","year":"2015","journal-title":"Curr Treat Options Neurol."},{"key":"2021062118210887400_i1537-2073-23-3-101-b20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1352458518754364","article-title":"Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: a multicentre, Italian, retrospective, observational study","volume":"25","author":"Baroncini","year":"2019","journal-title":"Mult Scler."},{"key":"2021062118210887400_i1537-2073-23-3-101-b21","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1212\/WNL.0000000000002880","article-title":"International Pediatric MS Study Group Global Members Symposium report","volume":"87","author":"Wassmer","year":"2016","journal-title":"Neurology."}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/23\/3\/101\/2848559\/i1537-2073-23-3-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/23\/3\/101\/2848559\/i1537-2073-23-3-101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:05Z","timestamp":1752786725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/utilization-and-treatment-patterns-of-disease-modifying-therapy-in-pediatric-patients-with-multiple-sclerosis-in-the-united-states"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,6,2]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2019-095","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}